EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: The fourth in a series of post hoc analyses of the phase III clinical study data

Sue Ellen Cox iD, Benjamin Ascher, Rui L Avelar, Kenneth R Beer, Jean Carruthers, Hugues Cartier, Steven Fagien, Nowell Solish

Journal of Cosmetic Dermatology · 2023

DOI: 10.1111/jocd.15783 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Sue Ellen Cox und 7 weiteren Autor:innen. Beteiligte Einrichtung: Aesthetic Solutions, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Agents, Skin Aging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Evolus, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the absence of Phase III clinical trial data to support their use, 3.4% of all neurotoxin treatments performed internationally for esthetic purposes in 2020 were performed in patients 65 years of age and older.

Objectives

To investigate the efficacy and safety of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in the subset of Phase III clinical trial participants who were 65 years of age and older.

Methods

Post hoc analyses were performed on all patients who had been treated with a single dose of 20 U prabotulinumtoxinA in the three 150‐day, placebo‐controlled Phase III glabellar line clinical studies. Patients were grouped by age: ≥65 years ( n = 70) versus

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ANeuromuscular AgentsSkin AgingHumansAdultAgedForeheadNeurotoxinsTreatment OutcomeDouble-Blind Method

Stichwörter der Autor:innen

botulinum toxin type Aglabellar linespatients ≥65 yearsprabotulinumtoxinA

Substanzen

Botulinum Toxins, Type ANeuromuscular AgentsNeurotoxins

Autor:innen und Institutionen

  • Aesthetic Solutions, Chapel Hill, North Carolina, USA.
  • Department of Dermatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Dermatology, Duke University Medical Center, Chapel Hill, North Carolina, USA.
  • Paris Academy, Paris, France.
  • Evolus, Inc., Newport Beach, California, USA.
  • Department of Clinical Research, Research Institute of the Southeast, West Palm Beach, Florida, USA.

ORCID-Profile: Sue Ellen Cox

Förderung

  • Evolus, Inc.

Zitieren

APA

Cox, S. E., Ascher, B., Avelar, R. L., Beer, K. R., Carruthers, J., Cartier, H., Fagien, S., & Solish, N. (2023). PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: The fourth in a series of post hoc analyses of the phase III clinical study data. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15783

Vancouver

Cox SE, Ascher B, Avelar RL, Beer KR, Carruthers J, Cartier H, et al. PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: The fourth in a series of post hoc analyses of the phase III clinical study data. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15783

BibTeX
@article{Cox2023,
  author = {Cox, Sue Ellen and Ascher, Benjamin and Avelar, Rui L and Beer, Kenneth R and Carruthers, Jean and Cartier, Hugues and Fagien, Steven and Solish, Nowell},
  title = {PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: The fourth in a series of post hoc analyses of the phase III clinical study data},
  journal = {Journal of Cosmetic Dermatology},
  year = {2023},
  doi = {10.1111/jocd.15783}
}
Kostenlos starten →